![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ALPHARMA AND SYNTHON PHARMACEUTICALS ANNOUNCE CO-PROMOTION AGREEMENT
ALPHARMA AND SYNTHON PHARMACEUTICALS ANNOUNCE CO-PROMOTION AGREEMENT
Alpharma and Synthon Pharmaceuticals have announced that Alpharma's sales force will co-promote Synthon's Pexeva. Pexeva is a branded selective serotonin reuptake inhibitor for the treatment of depression, obsessive/compulsive disorder, and/or panic disorder. Pexeva was launched by Synthon in February 2004, and is supported by a specialist sales force focusing on psychiatry. Alpharma will promote this product along with its current branded product Kadian.
Yahoo News (http://biz.yahoo.com/prnews/050113/nyth078_2.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct